Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03741101 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib(plexifpc) | unknown | Phase 2 | 15 | Region SkaneOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06353581 | Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | unknown | Phase 2 | 78 | Yonsei UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03721744 | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 336 | 1Globe Health Institute LLCINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341530 | Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341660 | To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341842 | Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity(PROTECT) | unknown | Phase 2 | 316 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05057130 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | unknown | Phase 2 / Phase 3 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339242 | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 30 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04209868 | Preoperative Paravertebral Block in Cancer Surgery of the Lung(ParaSOL) | unknown | Phase 2 / Phase 3 | 100 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06332287 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 25 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03412409 | RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04543695 | A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | unknown | Phase 2 | 255 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06331650 | A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06202716 | Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore | unknown | Phase 2 | 50 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328049 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | unknown | Phase 2 | 30 | Taixing People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328387 | HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | unknown | Phase 1 / Phase 2 | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06279494 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | unknown | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT06322563 | Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06324266 | Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation | unknown | Phase 2 / Phase 3 | 80 | Jinling Hospital, ChinaOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320301 | Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | unknown | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT05669586 | Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer | unknown | Phase 2 | 50 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06304987 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | unknown | Phase 2 | 50 | Beijing Friendship HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 27 | Mahidol UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04163419 | Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis | unknown | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04249739 | Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive | unknown | Phase 2 | 93 | Samsung Medical CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06308939 | Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | unknown | Phase 2 | 81 | Zhejiang Cancer HospitalOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | unknown | Phase 1 / Phase 2 | 121 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05387616 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden(Alternative-C) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2024source: clinicaltrials